However, translation of these findings to adult human obesity remains constrained by fundamental physiological differences, including limited brown adipose tissue mass and reduced thermogenic capacity
Currently, semaglutide is in shortage, and tirzepatide was previously in shortage but is no longer
Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site
The MHRA has taken enforcement action against illicit supply chains, including a major seizure of unlicensed weight loss pens in October 2025
however, the active ingredient semaglutide is FDA-approved, and compounding pharmacies operate under FDA and state regulations
The safest approach is to start the injectable escalation protocol from the beginning